Vtv Theraptcs Cl A (VTVT) Stock Price, Quote & News

Company Profile

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a lic...

Industry: Biotechnology

Sector: Healthcare

Phone: 336 841 0300

Fax: 336 841 0310

Website: vtvtherapeutics.com

Address:

3980 Premier Drive, Suite 310, High Point, United States

GDS_investing Aug. 3 at 7:13 PM

$VTVT 150,000

0 · Reply

Newtrader_covid19 Aug. 3 at 5:15 PM

$VTVT earlier they said 3Q, but no further update. https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-fourth-quarter-and-full-year-2025

0 · Reply

Newtrader_covid19 Aug. 3 at 5:12 PM

$VTVT without FDA approval this is not going to run. They are also not giving any timeline for completion of trial.

0 · Reply

GDS_investing Aug. 3 at 4:55 PM

$VTVT volume is running up 100K

0 · Reply

GDS_investing Aug. 3 at 3:25 PM

$VTVT .

0 · Reply

radsl Aug. 2 at 4:52 PM

$VTVT Been a long term holder I can't understand why this company does not have any PR IR or keep the shareholders informed. https://campfieldtx.com/news/series-a-launch

0 · Reply

dcajic2 Jul. 31 at 5:11 PM

$VTVT good volume but stain the stock is down on no news. Could this be a big problem since people are selling.

0 · Reply

GDS_investing Jul. 31 at 3:41 PM

$VTVT huge volume so 65,000 on the move. very low float long targets 44 56 84 120 240 480 fda

0 · Reply

dcajic2 Jul. 30 at 5:30 PM

$VTVT They say data in Q3 so could still be several months before any news. No news in the next few weeks the stock will go below $30. I will be a buyer below $30.

0 · Reply

GDS_investing Jul. 30 at 4:48 PM

$VTVT on the move reversal mode a lot of room to run 44- 56 - 84 120 240 480 after FDA very low float read all my posts about VTVT LONG $VTVT and $AGEN $MSFT $SNDK $NBIS

0 · Reply

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

2026-07-16T11:20:34.000Z - 18 days ago

vTv Therapeutics price target raised to $57 from $49 at BTIG

2026-06-30T12:26:19.000Z - 4 weeks ago

vTv Therapeutics initiated with a Buy at Rodman & Renshaw

Jun 26, 2026, 11:00 AM EDT - 5 weeks ago

vTv Therapeutics Transcript: AGM 2026

Jun 10, 2026, 8:00 AM EDT - 7 weeks ago

vTv Therapeutics Proxy statement: Proxy filing

Jun 3, 2026, 5:05 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:05 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:04 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:04 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:03 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:01 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 3, 2026, 5:01 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:02 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 11:01 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 10:58 AM EDT - 2 months ago

vTv Therapeutics Earnings release

Jun 1, 2026, 10:56 AM EDT - 2 months ago

vTv Therapeutics Earnings release

2026-05-13T20:13:15.000Z - 2 months ago

vTv Therapeutics reports Q1 EPS $1.65, consensus 21c

May 13, 2026, 4:01 PM EDT - 2 months ago

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 7, 2026, 8:00 AM EDT - 3 months ago

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Mar 23, 2026, 2:00 PM EDT - 4 months ago

vTv Therapeutics Transcript: 38th Annual Roth Conference

Mar 16, 2026, 8:00 AM EDT - 5 months ago

vTv Therapeutics to Participate in the 38th Annual ROTH Conference

2026-03-12T10:46:05.000Z - 5 months ago

vTv Therapeutics initiated with an Outperform at Evercore ISI

2026-03-11T11:11:56.000Z - 5 months ago

vTv Therapeutics price target raised to $55 from $35 at Alliance Global

2026-03-10T20:11:02.000Z - 5 months ago

vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)

Mar 10, 2026, 4:01 PM EDT - 5 months ago

vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Mar 3, 2026, 9:50 AM EST - 5 months ago

vTv Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 13, 2026, 8:00 AM EST - 6 months ago

vTv Therapeutics to Participate in Upcoming Investor Conferences

2026-02-02T13:15:17.000Z - 6 months ago

vTv Therapeutics expanded its license agreement with Newsoara Biopharma

Feb 2, 2026, 8:00 AM EST - 6 months ago

vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737

2026-01-27T12:25:32.000Z - 6 months ago

vTv Therapeutics price target raised to $49 from $40 at BTIG

2026-01-22T21:11:50.000Z - 6 months ago

vTv Therapeutics initiated with a Buy at Roth Capital

2026-01-05T10:50:07.000Z - 7 months ago

vTv Therapeutics initiated with a Buy at TD Cowen

2025-12-19T13:20:18.000Z - 8 months ago

vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright

2025-12-18T21:10:54.000Z - 8 months ago

vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi

Dec 18, 2025, 4:05 PM EST - 8 months ago

vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health

2025-11-18T21:20:58.000Z - 9 months ago

vTv Therapeutics initiated with a Buy at BTIG

2025-11-06T22:30:59.000Z - 9 months ago

vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)

Nov 6, 2025, 4:15 PM EST - 9 months ago

vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-05T14:42:37.000Z - 9 months ago

vTv Therapeutics trading resumes

2025-11-05T14:36:57.000Z - 9 months ago

vTv Therapeutics trading halted, volatility trading pause

2025-10-09T12:11:55.000Z - 10 months ago

vTv Therapeutics announces three appointments to Scientific Advisory Board

Oct 9, 2025, 8:00 AM EDT - 10 months ago

vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

2025-10-03T20:45:20.000Z - 10 months ago

vTv Therapeutics files to sell 15.88M shares of Class A common stock for holders

2025-09-17T14:00:38.000Z - 11 months ago

vTv Therapeutics trading resumes

2025-09-17T13:55:25.000Z - 11 months ago

vTv Therapeutics trading halted, volatility trading pause

Sep 15, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

Sep 3, 2025, 4:57 PM EDT - 11 months ago

UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 3, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics to Participate in Upcoming September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 11 months ago

vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Aug 12, 2025, 4:15 PM EDT - 1 year ago

vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

Aug 7, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

Jun 11, 2025, 8:00 AM EDT - 1 year ago

vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series

May 19, 2025, 9:00 AM EDT - 1 year ago

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin

May 15, 2025, 4:01 PM EDT - 1 year ago

vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

May 15, 2025, 12:00 PM EDT - 1 year ago

vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes

Mar 20, 2025, 5:35 PM EDT - 1 year ago

vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 17, 2025, 8:30 AM EDT - 1 year ago

vTv Therapeutics Announces FDA has Lifted Clinical Hold on Cadisegliatin Program for Diabetes

Dec 9, 2024, 7:33 AM EST - 1 year ago

CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

Dec 2, 2024, 4:05 PM EST - 1 year ago

vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference

Aug 8, 2024, 4:15 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update

Jul 26, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

Jun 24, 2024, 4:05 PM EDT - 2 years ago

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

May 28, 2024, 8:00 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING

May 9, 2024, 4:51 PM EDT - 2 years ago

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update

Mar 19, 2024, 8:30 AM EDT - 2 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT

Mar 13, 2024, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Mar 4, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

Mar 1, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference

Feb 28, 2024, 8:00 AM EST - 2 years ago

vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund

Feb 22, 2024, 4:00 PM EST - 2 years ago

CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE

Nov 9, 2023, 4:30 PM EST - 2 years ago

vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2023, 8:00 AM EST - 2 years ago

vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer

Nov 1, 2023, 8:00 AM EDT - 2 years ago

vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million

Sep 27, 2023, 8:30 AM EDT - 3 years ago

CANTEX AND MICHIGAN MEDICINE ANNOUNCE INITIATION OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 3 PIVOTAL CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF AZELIRAGON IN THE TREATMENT OF PATIENTS HOSPITALIZED FOR COVID-19

$Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer$

Sep 26, 2023, 8:30 AM EDT - 3 years ago

Cantex and Allegheny Health Network Announce Initiation of a Phase 1/2 Study of Azeliragon in Patients Refractory to First-Line Treatment of Metastatic Pancreatic Cancer

Sep 18, 2023, 8:30 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS AND LENOX HILL HOSPITAL ANNOUNCE INITIATION OF A PHASE 2 STUDY OF RAGE INHIBITOR AZELIRAGON AS A FRONT-LINE TREATMENT FOR UNMETHYLATED GLIOBLASTOMA

Aug 11, 2023, 4:30 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update

Aug 10, 2023, 8:33 AM EDT - 3 years ago

Cantex Pharmaceuticals Announces Article Published in npj Breast Cancer Highlighting Potential Role of RAGE Inhibition to Prevent Metastasis in Triple-Negative Breast Cancer

Jun 16, 2023, 8:00 AM EDT - 3 years ago

vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline

Jun 15, 2023, 7:33 AM EDT - 3 years ago

CANTEX PHARMACEUTICALS TO PRESENT AT THE MEDINVEST ONCOLOGY INVESTOR CONFERENCE IN BOSTON

May 24, 2023, 9:00 AM EDT - 3 years ago

vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals

May 11, 2023, 4:15 PM EDT - 3 years ago

vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update

Apr 20, 2023, 8:00 AM EDT - 3 years ago

Cantex and Michigan Medicine Announce Initiation of a Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Clinical Study to Determine the Safety and Efficacy of Azeliragon in the Treatment of Patients Hospitalized for COVID-19

GDS_investing Aug. 3 at 7:13 PM

$VTVT 150,000

0 · Reply

Newtrader_covid19 Aug. 3 at 5:15 PM

$VTVT earlier they said 3Q, but no further update. https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-fourth-quarter-and-full-year-2025

0 · Reply

Newtrader_covid19 Aug. 3 at 5:12 PM

$VTVT without FDA approval this is not going to run. They are also not giving any timeline for completion of trial.

0 · Reply

GDS_investing Aug. 3 at 4:55 PM

$VTVT volume is running up 100K

0 · Reply

GDS_investing Aug. 3 at 3:25 PM

$VTVT .

0 · Reply

radsl Aug. 2 at 4:52 PM

$VTVT Been a long term holder I can't understand why this company does not have any PR IR or keep the shareholders informed. https://campfieldtx.com/news/series-a-launch

0 · Reply

dcajic2 Jul. 31 at 5:11 PM

$VTVT good volume but stain the stock is down on no news. Could this be a big problem since people are selling.

0 · Reply

GDS_investing Jul. 31 at 3:41 PM

$VTVT huge volume so 65,000 on the move. very low float long targets 44 56 84 120 240 480 fda

0 · Reply

dcajic2 Jul. 30 at 5:30 PM

$VTVT They say data in Q3 so could still be several months before any news. No news in the next few weeks the stock will go below $30. I will be a buyer below $30.

0 · Reply

GDS_investing Jul. 30 at 4:48 PM

$VTVT on the move reversal mode a lot of room to run 44- 56 - 84 120 240 480 after FDA very low float read all my posts about VTVT LONG $VTVT and $AGEN $MSFT $SNDK $NBIS

0 · Reply

Bullfinch Jul. 30 at 4:58 AM

$VTVT https://ir.vtvtherapeutics.com/sec-filings/sec-filing/schedule-13ga/0001104659-26-088300

0 · Reply

dcajic2 Jul. 29 at 6:23 PM

$VTVT where do the buyers come from? No news whatsoever

0 · Reply

dcajic2 Jul. 29 at 6:22 PM

$VTVT Very good volume. Why would so many people be selling if they thought for a moment the stock was bullish

0 · Reply

GDS_investing Jul. 29 at 5:38 PM

$VTVT 170,000 lets see 200,000 today

0 · Reply

GDS_investing Jul. 29 at 5:11 PM

$VTVT 160,000

0 · Reply

GDS_investing Jul. 29 at 5:09 PM

$VTVT watch $AGEN $XE $RFL all long

0 · Reply

GDS_investing Jul. 29 at 4:52 PM

$VTVT VOLUME ALERT very high volume today low float volume is the key long 44 56 84 120 240 480 after FDA

0 · Reply

Bullfinch Jul. 28 at 8:06 PM

$VTVT https://ir.vtvtherapeutics.com/news-releases/news-release-details/vtv-therapeutics-announces-inducement-grants-under-nasdaq-3

0 · Reply

dcajic2 Jul. 28 at 5:16 PM

$VTVT not sure why someone would say this company is a gift management communication is so very poor. It could still be months and months away from getting any news at all. I did say it was a better buy under $30.

0 · Reply

dcajic2 Jul. 28 at 5:15 PM

$VTVT Short worked out again. Not sure what exactly is bullish. Higher volume yet lower price. If people were really bullish why would they be selling.

0 · Reply

GDS_investing Jul. 28 at 4:39 PM

$VTVT add more 150 shares this price is a gift imo buy support area LONG

0 · Reply

dcajic2 Jul. 27 at 5:29 PM

$VTVT Where is the news? Why people selling it such good news is coming?

0 · Reply

Market Cap	127.42M
Revenue (ttm)	0.00
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	171,100
Avg Vol	69,088
Day's Range	N/A - N/A
Shares Out	3.94M
Stochastic %K	72%
Beta	0.25
Analysts	Strong Sell
Price Target	$56.14